NYSE:BHC Bausch Health Companies (BHC) Stock Forecast, Price & News $8.23 +0.03 (+0.37%) (As of 06/2/2023 ET) Add Compare Share Share Today's Range$8.09▼$8.3850-Day Range$5.72▼$8.8052-Week Range$4.00▼$10.23Volume2.13 million shsAverage Volume4.57 million shsMarket Capitalization$2.98 billionP/E RatioN/ADividend YieldN/APrice Target$8.88 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Bausch Health Companies MarketRank™ ForecastAnalyst RatingHold2.00 Rating ScoreUpside/Downside7.8% Upside$8.88 Price TargetShort InterestBearish6.65% of Float Sold ShortDividend StrengthN/ASustainability-1.42Upright™ Environmental ScoreNews Sentiment1.29Based on 3 Articles This WeekInsider TradingN/AProj. Earnings Growth11.99%From $3.17 to $3.55 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.90 out of 5 starsMedical Sector655th out of 983 stocksPharmaceutical Preparations Industry327th out of 486 stocks 1.0 Analyst's Opinion Consensus RatingBausch Health Companies has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 4 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $8.88, Bausch Health Companies has a forecasted upside of 7.8% from its current price of $8.23.Amount of Analyst CoverageBausch Health Companies has received no research coverage in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted6.65% of the float of Bausch Health Companies has been sold short.Short Interest Ratio / Days to CoverBausch Health Companies has a short interest ratio ("days to cover") of 5.4.Change versus previous monthShort interest in Bausch Health Companies has recently increased by 1.11%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldBausch Health Companies does not currently pay a dividend.Dividend GrowthBausch Health Companies does not have a long track record of dividend growth. Previous Next 4.0 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreBausch Health Companies has received a 55.47% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Allergy eye drops", "Anti-diarrheal and intestinal anti-inflammatory medication (A07)", "Laxatives", and "Intraocular lenses" products. See details.Environmental SustainabilityThe Environmental Impact score for Bausch Health Companies is -1.42. Previous Next 3.5 News and Social Media Coverage News SentimentBausch Health Companies has a news sentiment score of 1.29. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Bausch Health Companies this week, compared to 3 articles on an average week.Search Interest42 people have searched for BHC on MarketBeat in the last 30 days. This is an increase of 121% compared to the previous 30 days.MarketBeat Follows10 people have added Bausch Health Companies to their MarketBeat watchlist in the last 30 days. This is an increase of 67% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Bausch Health Companies insiders have not sold or bought any company stock.Percentage Held by Insiders13.75% of the stock of Bausch Health Companies is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions66.99% of the stock of Bausch Health Companies is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 2.5 Earnings and Valuation Earnings GrowthEarnings for Bausch Health Companies are expected to grow by 11.99% in the coming year, from $3.17 to $3.55 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Bausch Health Companies is -8.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Bausch Health Companies is -8.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Growth RatioBausch Health Companies has a PEG Ratio of 0.13. PEG Ratios below 1 indicate that a company could be undervalued.Price to Book Value per Share RatioBausch Health Companies has a P/B Ratio of 20.58. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Bausch Health Companies (NYSE:BHC) StockBausch Health Cos., Inc. engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: Salix, International, Solta Medical, Diversified Products, and Bausch + Lomb. The Salix segment consists of sales in the U.S. of GI products. Sales of the Xifaxan product line. The International segment comprises of sales, with the exception of sales of Bausch + Lomb products and Solta aesthetic medical devices, outside the U.S and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical and OTC products. The Solta Medical segment refer to global sales of Solta Medical aesthetic medical devices. The Diversified Products segment covers sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, generic products, ortho dermatologics, and dentistry products. The Bausch + Lomb segment are global sales of Bausch + Lomb vision care, surgical and ophthalmic pharmaceuticals products. The company was founded on March 29, 1994 and is headquartered in Laval, Canada.Read More Receive BHC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bausch Health Companies and its competitors with MarketBeat's FREE daily newsletter. Email Address BHC Stock News HeadlinesMay 18, 2023 | marketbeat.comZoetis Declares New Dividend, Hinting At Undervaluation (BHC)Zoetis shareholders woke up to news of JAB's acquisition of Pumpkin, a per insurance platform where Zoetis owns a minority stake. 2023 outlooks suggest a rallyMay 31, 2023 | finance.yahoo.comOraPharma and Alex Rodriguez Team Up to Raise Awareness About the Importance of Managing Gum DiseaseJune 3, 2023 | Behind the Markets (Ad)66,000% upside on tiny biotech?The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.May 29, 2023 | ca.finance.yahoo.comBausch Health: Prescription for Profits or Risky Business?May 22, 2023 | americanbankingnews.comBausch Health Companies (NYSE:BHC) Price Target Raised to $9.50May 20, 2023 | americanbankingnews.comStockNews.com Begins Coverage on Bausch Health Companies (NYSE:BHC)May 20, 2023 | americanbankingnews.comBausch Health Companies (NYSE:BHC) Trading Up 6.6%May 20, 2023 | americanbankingnews.comBausch Health Companies Sees Unusually Large Options Volume (NYSE:BHC)June 3, 2023 | Behind the Markets (Ad)66,000% upside on tiny biotech?The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.May 19, 2023 | finance.yahoo.com15 Best Stocks to Buy and Hold According to Billionaire Carl IcahnMay 18, 2023 | finance.yahoo.comBausch (BHC) Gains on Court Ruling for Xifaxan Against NorwichMay 18, 2023 | msn.comBausch Health Options Traders: Stock Will Remain Below This Level Through July ExpirationMay 18, 2023 | finance.yahoo.comNew Clinical Study Suggests the Use of OraPharma’s ARESTIN(R) (minocycline HCl) Microspheres, 1mg May Decrease Certain Pathogens in Adults with PeriodontitisMay 18, 2023 | finance.yahoo.comThe 6.3% return this week takes Bausch + Lomb's (NYSE:BLCO) shareholders one-year gains to 18%May 18, 2023 | msn.comWhy Bausch Health Shares Soared Over 24% TodayMay 17, 2023 | msn.comBausch Health stock soars after company says rival application for generic version of its IBS drug can’t be approved until 2029May 17, 2023 | finance.yahoo.comU.S. District Court Upholds Final Judgment for XIFAXAN(R) 550 mg That Prevents FDA Approval of Norwich’s Abbreviated New Drug Application Until 2029May 17, 2023 | finance.yahoo.comWhy Shares of Bausch Health Soared WednesdayMay 14, 2023 | americanbankingnews.comTraders Buy Large Volume of Bausch Health Companies Put Options (NYSE:BHC)May 10, 2023 | seekingalpha.comBausch Health: Bullish On Long-Term Prospects, Awaiting Subsiding HeadwindsMay 10, 2023 | americanbankingnews.comBausch Health Companies (NYSE:BHC) and Biophytis (NASDAQ:BPTS) Head to Head ReviewMay 9, 2023 | seekingalpha.comBausch Health: There's Still UncertaintyMay 8, 2023 | finanznachrichten.deBausch Health Companies Inc.: Salix Pharmaceuticals to Deliver Podium Presentation at Digestive Disease Week 2023May 8, 2023 | finance.yahoo.comSalix Pharmaceuticals to Deliver Podium Presentation at Digestive Disease Week(R) 2023May 4, 2023 | msn.comBausch Health stock falls ~15% as Q1 net loss widens amid revenue missMay 4, 2023 | cnbc.comBausch Health's quarter disappoints, guidance beats. But uncertainty prevails over patent litigationMay 4, 2023 | americanbankingnews.comStockNews.com Downgrades Bausch Health Companies (NYSE:BHC) to HoldSee More Headlines BHC Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BHC Company Calendar Last Earnings8/02/2021Today6/02/2023Next Earnings (Estimated)8/08/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNYSE:BHC CUSIPN/A CIK885590 Webwww.bauschhealth.com Phone(514) 744-6792Fax514-744-6272Employees19,900Year FoundedN/APrice Target and Rating Average Stock Price Forecast$8.88 High Stock Price Forecast$12.00 Low Stock Price Forecast$6.00 Forecasted Upside/Downside+7.8%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($0.98) Trailing P/E RatioN/A Forward P/E Ratio2.60 P/E Growth0.13Net Income$-225,000,000.00 Net Margins-4.38% Pretax Margin-2.25% Return on Equity381.67% Return on Assets3.94% Debt Debt-to-Equity Ratio139.36 Current Ratio1.08 Quick Ratio0.77 Sales & Book Value Annual Sales$8.12 billion Price / Sales0.37 Cash Flow$7.22 per share Price / Cash Flow1.14 Book Value$0.40 per share Price / Book20.58Miscellaneous Outstanding Shares362,040,000Free Float312,257,000Market Cap$2.98 billion OptionableOptionable Beta0.95 Key ExecutivesThomas J. AppioChief Executive Officer & DirectorMirza DautbegovicChief Operating Officer & Senior Vice PresidentTom G. VadakethChief Financial Officer & Executive Vice PresidentTage RamakrishnaChief Medical Officer, President-R&DSeana-Lyn CarsonExecutive Vice President & General CounselKey CompetitorsSage TherapeuticsNASDAQ:SAGEZai LabNASDAQ:ZLABAxsome TherapeuticsNASDAQ:AXSMImmunoGenNASDAQ:IMGNPTC TherapeuticsNASDAQ:PTCTView All CompetitorsInsiders & InstitutionsJPMorgan Chase & Co.Bought 5,424 shares on 5/18/2023Ownership: 0.014%Thrivent Financial for LutheransBought 183,903 shares on 5/17/2023Ownership: 0.051%Geode Capital Management LLCSold 94,934 shares on 5/16/2023Ownership: 0.085%SIG North Trading ULCSold 71,400 shares on 5/16/2023Ownership: 0.000%First Trust Advisors LPBought 34,658 shares on 5/16/2023Ownership: 0.026%View All Insider TransactionsView All Institutional Transactions BHC Stock - Frequently Asked Questions Should I buy or sell Bausch Health Companies stock right now? 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Bausch Health Companies in the last twelve months. There are currently 4 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" BHC shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in BHC, but not buy additional shares or sell existing shares. View BHC analyst ratings or view top-rated stocks. What is Bausch Health Companies' stock price forecast for 2023? 4 Wall Street analysts have issued 1 year price objectives for Bausch Health Companies' stock. Their BHC share price forecasts range from $6.00 to $12.00. On average, they predict the company's share price to reach $8.88 in the next twelve months. This suggests a possible upside of 7.8% from the stock's current price. View analysts price targets for BHC or view top-rated stocks among Wall Street analysts. How have BHC shares performed in 2023? Bausch Health Companies' stock was trading at $6.28 at the beginning of the year. Since then, BHC stock has increased by 31.1% and is now trading at $8.23. View the best growth stocks for 2023 here. Are investors shorting Bausch Health Companies? Bausch Health Companies saw a decrease in short interest in the month of April. As of April 30th, there was short interest totaling 23,350,000 shares, a decrease of 8.7% from the April 15th total of 25,580,000 shares. Based on an average trading volume of 4,300,000 shares, the short-interest ratio is presently 5.4 days. Approximately 6.6% of the company's stock are short sold. View Bausch Health Companies' Short Interest. When is Bausch Health Companies' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 8th 2023. View our BHC earnings forecast. How were Bausch Health Companies' earnings last quarter? Bausch Health Companies Inc. (NYSE:BHC) announced its earnings results on Monday, August, 2nd. The company reported $0.97 earnings per share for the quarter, beating analysts' consensus estimates of $0.95 by $0.02. The business earned $2.10 billion during the quarter, compared to the consensus estimate of $2.12 billion. Bausch Health Companies had a positive trailing twelve-month return on equity of 381.67% and a negative net margin of 4.38%. What guidance has Bausch Health Companies issued on next quarter's earnings? Bausch Health Companies updated its FY 2023 earnings guidance on Thursday, May, 4th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $8.35 billion-$8.55 billion, compared to the consensus revenue estimate of $8.35 billion. What is Joseph C. Papa's approval rating as Bausch Health Companies' CEO? 43 employees have rated Bausch Health Companies Chief Executive Officer Joseph C. Papa on Glassdoor.com. Joseph C. Papa has an approval rating of 97% among the company's employees. This puts Joseph C. Papa in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Bausch Health Companies own? Based on aggregate information from My MarketBeat watchlists, some companies that other Bausch Health Companies investors own include Gilead Sciences (GILD), Micron Technology (MU), Constellation Software (CSU), Intact Financial (IFC), NVIDIA (NVDA), Netflix (NFLX), Alibaba Group (BABA), Tesla (TSLA), Advanced Micro Devices (AMD) and Bank of America (BAC). What is Bausch Health Companies' stock symbol? Bausch Health Companies trades on the New York Stock Exchange (NYSE) under the ticker symbol "BHC." Who are Bausch Health Companies' major shareholders? Bausch Health Companies' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Franklin Resources Inc. (4.59%), Goldentree Asset Management LP (4.57%), National Bank of Canada FI (3.63%), Healthcare of Ontario Pension Plan Trust Fund (2.76%), ING Groep NV (2.08%) and Mizuho Markets Cayman LP (1.93%). Insiders that own company stock include Amy B Wechsler, Christina Ackermann, Holdings LP Valueact, Joseph F Gordon, Robert Spurr, Russell Barrans, Sam Eldessouky, Schutter Richard U De, Seana Carson, Steven D Miller and William D Humphries. View institutional ownership trends. How do I buy shares of Bausch Health Companies? Shares of BHC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Bausch Health Companies' stock price today? One share of BHC stock can currently be purchased for approximately $8.23. How much money does Bausch Health Companies make? Bausch Health Companies (NYSE:BHC) has a market capitalization of $2.98 billion and generates $8.12 billion in revenue each year. The company earns $-225,000,000.00 in net income (profit) each year or ($0.98) on an earnings per share basis. How many employees does Bausch Health Companies have? The company employs 19,900 workers across the globe. How can I contact Bausch Health Companies? Bausch Health Companies' mailing address is 2150 ST. ELZEAR BLVD. WEST, LAVAL A8, H7L 4A8. The official website for the company is www.bauschhealth.com. The company can be reached via phone at (514) 744-6792, via email at ir@bauschhealth.com, or via fax at 514-744-6272. This page (NYSE:BHC) was last updated on 6/3/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bausch Health Companies Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.